Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Lupus ; 28(13): 1566-1570, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31653191

RESUMEN

BACKGROUND: Intravenous immunoglobulin (IVIG) is prepared using purified human plasma. IVIG therapy has immunomodulatory effects on autoimmune diseases, including severe systemic lupus erythematosus (SLE). However, reports of its effects on large cohorts are scarce. METHODS: This single-center retrospective study included SLE patients treated with at least one IVIG cycle for SLE complications. Demographic data, indications, cycle numbers, and clinical improvement with IVIG were evaluated. SLE Disease Activity Index 2000 (SLEDAI-2K) scores were calculated at admission and after IVIG treatment in order to measure clinical improvement. RESULTS: Sixty-three SLE patients treated with IVIG (median age: 29 years; interquartile range 21-36 years; 84.13% female) were included, who received 2 g/kg IVIG for two to five days. Main indications were immune thrombocytopenia, hypogammaglobulinemia, infection during a SLE flare, bicytopenia, and immune hemolytic anemia. Seven patients received more than one IVIG cycle without severe adverse effects. Significant differences were found in SLEDAI-2K scores when the indications were immune thrombocytopenia and hypogammaglobulinemia, with a trend for hemolytic anemia. Patients with concomitant infection, myopathy, and gastrointestinal involvement showed a considerable reduction in their last SLEDAI-2K scores. Fourteen patients died during hospitalization, mainly due to septic shock and active SLE. CONCLUSIONS: IVIG showed adequate tolerance and effectiveness in selected severe SLE manifestations, mainly hematological involvement. It was useful for concomitant infection.


Asunto(s)
Inmunoglobulinas Intravenosas/administración & dosificación , Factores Inmunológicos/administración & dosificación , Lupus Eritematoso Sistémico/tratamiento farmacológico , Adulto , Estudios de Cohortes , Femenino , Humanos , Inmunoglobulinas Intravenosas/efectos adversos , Factores Inmunológicos/efectos adversos , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/fisiopatología , Masculino , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Adulto Joven
2.
Int J Radiat Biol ; 95(9): 1337-1345, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31140889

RESUMEN

Aim: To explore the influence of electromagnetic fields (EMFs) on the cell cycle progression of MDA-MB-231 and MCF-7 breast cancer cell lines and to evaluate the radiosensitizing effect of magnetotherapy during therapeutic co-exposure to EMFs and radiotherapy. Material and methods: Cells were exposed to EMFs (25, 50 and 100 Hz; 8 and 10 mT). In the co-treatment, cells were first exposed to EMFs (50 Hz/10 mT) for 30 min and then to ionizing radiation (IR) (2 Gy) 4 h later. Cell cycle progression and free radical production were evaluated by flow cytometry, while radiosensitivity was explored by colony formation assay. Results: Generalized G1-phase arrest was found in both cell lines several hours after EMF exposure. Interestingly, a marked G1-phase delay was observed at 4 h after exposure to 50 Hz/10 mT EMFs. No cell cycle perturbation was observed after repeated exposure to EMFs. IR-derived ROS production was enhanced in EMF-exposed MCF-7 cells at 24 h post-exposure. EMF-exposed cells were more radiosensitive in comparison to sham-exposed cells. Conclusions: These results highlight the potential benefits of concomitant treatment with magnetotherapy before radiotherapy sessions to enhance the effectiveness of breast cancer therapy. Further studies are warranted to identify the subset(s) of patients who would benefit from this multimodal treatment.


Asunto(s)
Neoplasias de la Mama/patología , Campos Electromagnéticos , Ciclo Celular/efectos de la radiación , Relación Dosis-Respuesta en la Radiación , Humanos , Rayos Infrarrojos/uso terapéutico , Células MCF-7 , Magnetoterapia , Estrés Oxidativo/efectos de la radiación , Proyectos Piloto
3.
Rev Esp Enferm Apar Dig ; 75(3): 256-8, 1989 Mar.
Artículo en Español | MEDLINE | ID: mdl-2734471

RESUMEN

Sphincteroplasty is an internal biliary drainage technique that, along with choledochoduodenostomy, is offered to surgeons as one of the most effective techniques. We report our results and conclusions in a two-year study of a group of 46 patients. We prefer sphincteroplasty in the majority of patients with papillary sclerosis and consider it the most anatomic and physiologic drainage technique, since it eliminates the persistence of a cul de sac and the possible reflux of intestinal contents. It also permits examination of the sphincter of the Wirsung duct. We note that the classic complications of sphincteroplasty (acute pancreatitis and posterior window syndrome) are usually due to technical deficiencies.


Asunto(s)
Ampolla Hepatopancreática/patología , Colelitiasis/cirugía , Esfinterotomía Transduodenal , Colelitiasis/complicaciones , Femenino , Humanos , Masculino , Persona de Mediana Edad , Esclerosis
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda